Evidence map›Paper›PMID 38487570›Full record

ArticleFrontiers in psychiatry2024

Patient perspectives on current and potential therapies and clinical trial approaches for cocaine use disorder.

Suzanne Maahs, Denise Leclair, Baltazar Gomez-Mancilla, Brian D Kiluk, Velusamy Shanmuganathan Muthusamy, Partha S Banerjee, Shyamashree Dasgupta, Katherine M Waye

Open access · goldAbstract read
In one paragraph

Article in Frontiers in psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 4 countries.

Suzanne MaahsNovartis Biomedical Research, Cambridge, MA, United States.
Denise LeclairNovartis Pharmaceuticals Corporation, East Hanover, NJ, United States.
Baltazar Gomez-MancillaNovartis Biomedical Research, Neuroscience Research, Basel, Switzerland.
Brian D KilukYale School of Medicine, New Haven, CT, United States.
Velusamy Shanmuganathan MuthusamyNovartis Healthcare Pvt. Ltd., Hyderabad, Telangana, India.
Partha S BanerjeeNovartis Healthcare Pvt. Ltd., Hyderabad, Telangana, India.
Shyamashree DasguptaNovartis Healthcare Pvt. Ltd., Hyderabad, Telangana, India.
Katherine M WayeNovartis Biomedical Research, Cambridge, MA, United States.
Novartis (India) · INNovartis (United States) · USMcGill University · CAYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cocaine use disorder (CUD) is characterized by the continued use of cocaine despite serious impacts on life. This study focused on understanding the perspective of individuals with current CUD, individuals in CUD remission, and their supporters regarding current therapies, future therapies, and views on clinical trials for CUD. Methods: The online bulletin board (OBB) is a qualitative tool where participants engage in an interactive discussion on a virtual forum. Following completion of a screening questionnaire to determine eligibility, individuals in CUD remission and their supporters logged in to the OBB and responded to questions posed by the moderator. Individuals with current CUD participated in a one-time virtual focus group. Results: All individuals with current CUD and 94% of those in CUD remission reported a diagnosis consistent with CUD or substance use disorder during screening. Individuals with current CUD and their supporters were recruited from the United States (US). Individuals in CUD remission were recruited from five countries, including the US. Individuals with current CUD reported hesitation about seeking treatment due to stigma, a lack of privacy, and being labeled as a drug seeker; barriers to therapy included time, cost, and a lack of privacy. Participants wanted a safe therapy to stop cravings and withdrawal symptoms. Seven clinical trial outcomes, including long-term abstinence and craving control, were suggested based on collected insights. Conclusion: This study can help inform the design of clinical trials and emphasize the need for effective, safe, and accessible therapies. Recruiting participants will require significant trust building.

Indexed as

clinical trial outcomescocaine use disorderindividuals in cocaine use disorder remissionindividuals with current cocaine use disorderonline bulletin boardunmet needs

Identifiers

PMID38487570
PMCPMC10937549
OpenAlexW4392289782

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.